BACKGROUND
[0001] The field of the invention relates generally to devices for delivering fluids, such
as solutions, dispersions, suspensions, gels, pastes, or other like materials having
a broad range of viscosities.
[0002] In particular, the field of the invention relates to a system for multiple dose controlled
delivery of flowable materials. The system provides for unidirectional, laminar flow
to increase the rate of delivery at relatively low applied pressures. At the same
time the system prevents backflow and contamination of the flowable material from
air and airborne pathogens, or even from direct contact with microorganisms by immersion
in concentrated suspensions of viruses or bacteria, to thereby maintain the sterility
and integrity of a flowable material without the need for preservatives, antioxidants
or other additives.
[0003] The dispensing of flowable materials in a contamination-free manner, especially over
prolonged periods of time or in a repetitive manner, such as delivery of multiple
doses, presents many difficulties. A major problem to be overcome concerns precise
flow control and the prevention of backflow or reflux. External contaminants easily
can enter a container through the backflow effect at the end of a delivery cycle.
[0004] Many fluids including viscous solutions are delivered through a collapsible or volumetrically
reducible container which has a discharge port, such as a hole, nozzle, spout, or
other type of opening. The contents of the container, such as a viscous paste, liquid,
or other solution are delivered through the discharge port by internal pressure or
by squeezing the container. Such a conventional method of dispensing a viscous material
is inaccurate and fails to prevent the entry of external contaminants into the container
due to a backflow or reflux effect. That is, a conventional system for delivering
a fluid typically allows air to replace the fluid that is expressed. In addition,
as the volume of fluid in the container is reduced through successive delivery, flow
becomes inaccurate, uneven and difficult to control. Such a conventional delivery
system is highly undesirable when being used to administer a flowable material which
needs to be closely controlled. In addition, if the discharge port is used in a contaminated
environment, the entry of air, dust, filaments, airborne pathogens or microbes, quickly
can damage the integrity of the contents of the fluid.
[0005] For example, many flowable materials are highly labile. Labile substances are difficult
to preserve and break down quickly due to oxidation or hydrolysis. Many medications
lose their effectiveness quickly when exposed to repeated influx of air or external
contaminants in the course of regular use. In addition, many medications lose their
effectiveness when combined with antimicrobial agents.
[0006] Thus, what is needed is a system for delivering a labile, flowable material, such
as a medication, without danger of external contamination or loss of integrity due
to exposure to air, dust, filaments, airborne pathogens, or antimicrobial agents.
Such an improved delivery system would enhance the effectiveness of a labile medication,
such as an ophthalmic solution, and would be capable of maintaining sterility throughout
many uses over long periods of time. Such an improved delivery system also would effectively
maintain the integrity of a fluid throughout its period of use and would extend the
fluid's use life to that of its shelf life.
[0007] It has been found that the addition of some antimicrobial agents to labile medications
not only can shorten overall use life and effectiveness, but also may produce deleterious
side effects on a patient, such as delaying post-surgery healing rates. Conventional
approaches to dispensing a flowable medium while alleging to prevent air, airborne
pathogens or microbial contaminants from degrading the integrity of the flowable medium
have not demonstrated they can do so, nor prevent viruses or bacteria from entering
the dispensing container through contact or immersion. Therefore, it would be advantageous
to develop a system for delivery of a flowable medication without contamination, even
on direct contact with viruses or bacteria. Such a system would enable the medication
to be delivered free of antimicrobial agents and therefore would achieve an enhanced
therapeutic effect and a substantially prolonged use life.
[0008] It also would be advantageous to provide a system for delivery of a fluid, even a
highly viscous material at an improved flow rate, such that the unit dosage delivered
remained constant over time.
[0009] It also would be advantageous to provide an improved system for delivering a viscous
material, such as a paste, gel, or other viscous substance, in a highly controlled,
constant manner, irrespective of the change in volume of the volumetrically reducible
container through repeated usage.
[0010] It also would be advantageous to provide a system for delivering a highly viscous
material with a constant laminar flow and a simplified unidirectional flow path which
could be completely cut off after each use, preventing the entrapment of material
and providing a complete seal against contamination even by air or when in direct
contact with microbes.
[0011] What is also needed is a system for delivering a fluid, such that a predetermined
cracking pressure is achieved. The cracking pressure advantageously could be optimized
for ease of flow and ease of use. Alternatively, it would be desirable if the cracking
pressure also could be made higher, such as for impeding flow for safety considerations.
[0012] German utility model number DE-U-297 09 328 discloses a two-part closure device for
the outlet aperture of a container storing a flowable material, as specified in the
preamble of claim 1.
[0013] The foregoing and other disadvantages of conventional contamination-free delivery
systems may be seen with reference to
FIGS. 1A-1D. Referring to
FIG. 1A, Gerber, U.S. Patent No. 4,846,810 and Pardes, U.S. Patent No. 5,092,855 disclose
generally a valve or delivery system with central body core, delivery block or seat
as shown. The arrows indicate the flow of a flowable material into and through the
seat to its exit port. It is assumed that the container of flowable material is attached
to the entrance port of the valve and flowable material passes through the valve in
the path shown by the arrows. The container is not shown for the sake of simplicity.
As is well understood by those skilled in the art, an enclosing sleeve (not shown)
surrounds the valve body and constrains the flow of material in the direction shown
by the arrows. The enclosing sleeve retains an elastomeric sheath or seal against
the valve body, thereby providing a seal between the sheath and valve body. Note that
this design produces generally a convoluted flow path having at least four changes
of direction for the flowable material (please refer to
FIG. 1A).
[0014] In accordance with
FIG. 1A, each delivery system or valve operates through two sets of ports within the valve
body, thus rendering the flow path unnecessarily complex and unsuitable for viscous
applications. For example, viscous material may become lodged or retained between
the valve body and the enclosing sheath after use of the valve, thereby creating avenues
for the entry of airborne pathogens. In addition, the complex flow path constrains
the optimized delivery of a viscous material. In contrast, what is needed is a contamination-free
delivery system which not only prevents contamination or degradation of the flowable
material, but which also accelerates the flow rate of a viscous substance at low applied
pressures.
[0015] Another conventional delivery system is shown in
FIG. 1B. Haviv, U.S. Patent No. 5,080,138, discloses a valve assembly relying on a sleeve
valve and consisting of multiple components. Backflow is prevented by a sheath which
permits flowable material to flow out of the valve and attempts to prevent backflow
into the container. This device is not suitable for highly viscous solutions which
can prevent the sheath valve from returning to its closed position to block backflow
or reflux. Also, such a conventional delivery system creates a complicated flow path
with four changes of direction as shown by the arrows in
FIG. 1B. Such a device does not provide a high rate of flow or ease of flow of a viscous material.
It also fails to protect against contamination through immersion in or direct contact
with suspensions of viruses or bacteria.
[0016] Another example of a conventional delivery system is shown in
FIG. 1C. Debush, U.S. Patent No. 5,305,786 attempts to prevent contamination by an expandable
elastomeric sleeve tightly fitted about a valve body with entry and exit ports, as
shown by the arrows. However, this solution requires additional material to manufacture
the valve and produces a complex flow path, characterized by at least three changes
of direction, which is not suitable for delivering a viscous material. (See
FIG. 1C.)
[0017] FIG. 1D (U.S. Patent No. 5,836,484) shows a multiple-dose dispensing cartridge for contamination-safe
delivery of flowable materials. While this design has been proven effective against
airborne or microbial contamination, the design forces the fluid flow path to change
direction at least four times between the entry and exit of the fluid, as shown by
the arrows in
FIG. 1D. Each time the direction of the flow path changes, the velocity and flow rate of
the flowable material are reduced. In addition, such a convoluted flow path is not
suited to the delivery of large volumes of material. Additionally, a complex flow
path with frequent changes of direction is not at all suited to the delivery of a
viscous material. Not only would delivery of the viscous material require an inordinate
amount of pressure, the closure of the valve would be slowed by numerous pockets of
viscous material which could be trapped in the complex flow path. This could lead
to ineffective or uneven closing of the valve and may provide an avenue of entry for
air, airborne pathogens, or other microbes. In addition, any viscous material left
in the complex flow path which is exposed to the air may provide a source of contamination
for successive deliveries of that material.
[0018] None of the conventional dispensing devices shown generally in
FIGS. 1A-1D are simple in construction and capable of delivering a flowable material ranging
from low to high viscosity.
[0019] In addition, the conventional methods discussed above and as shown in
FIGS. 1A-1C may not be capable of maintaining a sterile condition once the apparatus is used
or opened to the atmosphere. This is particularly true of viscous solutions which
may be trapped in the tortuous flow path when the flow is shut off. A viscous solution
often does not permit an efficient sealing of the valve after use, and provides unconformities
and pathways for microorganisms such as a virus to enter and contaminate the contents
of the container.
[0020] Another problem in conventional systems for the delivery of a flowable medium is
the inability to achieve a constant flow rate. As the volume of a reducible reservoir
containing fluid is decreased, the flow rate of the fluid varies. In addition, the
cracking pressure or the pressure at which the viscous medium flows can be affected
by the amount of material in the container, the size of the container, the viscosity
of the fluid, the flow path of the fluid and like factors. Conventional delivery devices
have no way to maintain a constant flow rate.
[0021] What is needed is an improved method for delivering fluids of varying viscosity up
to many thousands of centipoise. What is also needed is a method and apparatus for
achieving an optimized cracking pressure for fluids of varying viscosity. That is,
it would be advantageous to set the cracking pressure for the delivery mechanism at
an optimal point for ease of activation, particularly for children and the elderly.
No conventional device addresses the need for a desired activation threshold to achieve
a desired cracking pressure and flow rate.
[0022] It also would be advantageous to achieve an optimized cracking pressure for a highly
viscous medium, while at the same time maintaining the integrity and sterility of
that medium and preventing contamination of that medium from any source, including
air or through direct contact even when immersed in suspensions of microbes, such
as viruses or bacteria. This advantageously would enable a labile, viscous, flowable
medium, such as a medication, to be reformulated without antimicrobial agents or other
additives, and to be delivered in a precise unit dose. The ability to deliver large
volumes of flowable media at an optimized cracking pressure also would allow for ease
of use.
[0023] With the exception of U.S. Patent No. 5,836,484, conventional delivery systems are
not scalable to permit high rates of delivery of large volumes of flowable media.
Therefore, what is also needed is a delivery system which not only would maintain
the sterility and integrity of the flowable medium, but at the same time enable its
rate of flow and cracking pressure to be closely controlled at desired values. It
also would be advantageous to provide a delivery system capable of achieving high
rates of flow of a highly viscous fluid by optimizing the cracking pressure, while
at the same time enabling the flow to be cut off completely, without reflux or any
contamination.
[0024] Another problem of conventional devices for delivering a flowable medium is the inability
to maintain the integrity of a flowable medium and to extend its useful life to that
of the shelf life. For example, conventional dispensing devices cannot maintain the
carbonation of a multiple use carbonated flowable medium. There is a gradual release
of carbonation each time the product is dispensed. Therefore, it also would be desirable
to provide a method for dispensing a flowable medium which maintained its integrity,
including carbonation or other inherent properties, and thereby extended the useful
life of the product.
SUMMARY
[0025] According to an aspect of the present invention, there is provided a device as specified
in claim 1.
[0026] A delivery system or device is disclosed that can be placed in an
in vivo or
in vitro fluid flow path, such as a catheter; a tissue or organ perfusion system; the neck
of a container, flexible bag or tube; or the outlet of a nozzle, syringe or piston,
and thereby controls the flow of fluid through or across the device along said flow
path. The delivery system can exist in either a closed or an open state. In the closed
state, flow is prevented through or across the device from both dirzctions. The flow
of fluid from the upstream side of the device is prevented from passing through or
across said device and neither fluid nor contaminants on the downstream side of the
device can pass through or across said device to the upstream side. In the open state,
flow is unidirectional. Fluid on the upstream side of the device can pass through
or across said device whereas neither fluid nor airborne or contact surface contaminants
on the downstream side of the device can pass through or across said device. The integrity
of the fluid on the upstream side of the device is maintained throughout numerous
flow cycles over extended periods of time from days to a year or more. If the upstream
fluid is initially sterile, the sterility of the remaining upstream fluid will be
maintained sterile throughout said numerous flow cycles.
[0027] The delivery device comprises at least two components, a plastic seat and an elastomeric
seal. In a closed state, the seal is tightly fitted to said seat and flow is prevented
through or across said delivery system. In an open state, said seal is separated from
said seat and unidirectional flow of fluid from the upstream side of the delivery
device can pass through or across said device whereas neither fluid nor airborne or
contact surface contaminants on the downstream side of the device can pass through
or across said device.
[0028] Separation of the seal from its seal-tight fit with the seat; i.e., the transition
from the closed to open state, occurs by applying either positive or negative pressure
on the seal or fluid held in the container. Depending on the orientation and configuration
of the seal and seat, positive or negative pressure will result in either the open
or closed state.
[0029] A positive pressure on the fluid in the upstream side of the device can be generated
by (1) applying pressure to the walls of a flexible reservoir containing said fluid
(e.g., a plastic tube or bag); (2) applying pressure directly on the fluid in a reducible
container (e.g., a piston or syringe); (3) the hydrostatic head of the fluid in said
reservoir; or (4) a fluid containing dissolved gas under pressure, such as a carbonated
beverage, in said reservoir.
[0030] A negative pressure on the downstream side of the seal can be generated by a force
field, either mechanical, electrical, magnetic, or a combination thereof, that results
in a separation of said seal from its tight fit with said seat.
[0031] The preferred embodiments in systems (1), (2) and (3) above place said seat on the
upstream side of the device and its seal on the downstream side. The preferred embodiment
of the cylindrical seat in systems (1) and (2) contains a central channel that leads
into one or more lateral channels ending in one or more exit ports. In the device's
closed state, exit port or ports are blocked by a cylindrical seal when said device
is in its closed state. The device's open state occurs by applying positive pressure
thereby producing a separation of the seal from the seat, allowing fluid to flow through
the seat, between the seal and the seat, and through or across the device.
[0032] The preferred embodiment of the seal in system (3) contains a perforation or bore
that is occluded by a coaxially aligned barrier surface in a mating engagement with
an adjacent seat when said device is in its closed state. The open state, wherein
the seal is separated from the seat, can be achieved by pulling the perforated seal
in the downstream direction away from its fit on the seat, thereby allowing said fluid
to flow through the seat, through the bore in the seal, and through or across the
delivery device.
[0033] The preferred embodiment in system (4) above places said seat on the downstream side
of the device and its seal on the upstream side. Said seal contains a perforation
or bore that is occluded by a barrier surface in the seat when said device is in its
closed state. The open state, wherein said seal is separated from said seat, is achieved
by pushing the perforated seal in the upstream direction away from its fit on the
seat thereby allowing said fluid to flow through the perforation in the seal, through
the vanes of the seat, and through or across the device.
[0034] In order to overcome the above discussed disadvantages of conventional contamination-safe
delivery systems for flowable materials, an aspect of the invention provides a contamination-safe
delivery system comprising an elastomeric seal and conformably engaging seat for providing
direct, unidirectional flow of the material wherein the area of the contact surface
of the delivery system to the volume of material passed is minimized to thereby minimize
friction, loss of velocity, and to maximize the flow rate of product. The configuration
of the seal and seat also completely eliminate the influx of air, airborne pathogens,
or any contaminant into the container of flowable medium to which the delivery device
is attached. The present delivery system also maintains the integrity and sterility
of a flowable material, even when challenged by direct contact through immersion in
suspensions of bacteria or viruses. The direct, linear flow path, according to this
aspect of the invention, minimizes internal resistance to flow and enables an optimal
flow rate and cracking pressure to be provided for various highly viscous substances.
[0035] Another aspect of the invention achieves greater control over the internal pressure
necessary to overcome the seal; that is, the cracking pressure, and enables the cracking
pressure to be optimized to allow both ease of flow or to make flow more difficult
when required, such as for safety applications.
[0036] In accordance with another aspect of the invention, the delivery device is highly
scalable in size and can work even for viscous fluids which are difficult to - flow.-
The present invention effectively delivers materials such as syrups, honey, lubricating
greases, petrogels, or other materials, with viscosities ranging from one centipoise
to thousands of centipoise.
[0037] Another aspect of the invention enables a flowable material to be reformulated without
preservatives, antioxidants, and so forth. This provides the advantage of an enhanced
therapeutic effect for many medications, especially those which are termed "labile."
Such an enhanced therapeutic effect is particularly valuable in eye care solutions.
Another aspect of the invention is the configuration of the delivery block or seat
which comprises a plurality of vanes extending radially outward from the seat. The
vanes provide a direct linear flow path for the delivery of the flowable material.
In addition, the seat can be configured to provide an optimized cracking pressure
for a particular application. For example, the surfaces of the vanes of the seat which
contact the elastomeric seal can be formed in a convex, arcuate shape, thereby imparting
a predetermined degree of stress to the conformably fitting elastomeric seal in order
to provide enhanced control of flow rate and cracking pressure.
[0038] In another aspect of the invention, the sterility of a sterile product such as Ultra
High Temperature (UHT) milk, and other dairy products including cheese sauces, cream,
and the like can be maintained without the need for refrigeration.
[0039] In yet another aspect, the invention regulates unidirectional flow of fluids including
gaseous materials such as natural gas. In particular, the invention may be used in
applications requiring precise unidirectional control of gas flow. The invention can
be used to control precisely the flow of inert gases, such as argon and helium. These
and other gases are used in the Chemical Vapor Deposition (CVD) process for fabrication
of semiconductor wafers.
[0040] In another aspect of the invention, the delivery system can be used to maintain the
carbonation of a carbonated flowable medium, such as carbonated soft drinks, beer,
or the like, even over repeated usage. This has the advantage of prolonging the useful
life of a carbonated beverage substantially to that of the beverage's shelf life.
In a particular application, the delivery system of the present invention can be used
in a public vending machine or soda fountain or the like. Even upon repeated use,
this aspect of the invention can protect the delivered product from contamination
by molds or yeast. This has valuable application in enabling a beverage, such as a
carbonated soft drink to be supplied directly from a vending machine, without the
need for separate packaging, such as in aluminum cans, for example. This aspect of
the invention has the advantage of saving large amounts of material in packaging beverages,
since the beverages now can be delivered safely without any contamination or loss
in carbonation. Thus, there would be no advantage to using cans, bottles, or other
containers for packaging beverages in a public vending machine or fountain application.
[0041] In another aspect of the invention, a molding process using an asymmetric mold design
and positioning of the gate in the mold are employed which eliminates knit lines and
parting lines from any sealing surface of the delivery system. This process is described
in copending U.S. Patent Application Serial No. 09/193,264 which is incorporated herein
by this reference. All knit lines, parting lines, and flash at the gate are minimized
to eliminate their occurrence at seal-seat contact surfaces. This substantially eliminates
any imperfections, unconformities, or discontinuities in these contact surfaces. This
has the effect of providing a seal, which is substantially impervious to backflow
even through direct contact by immersion in suspensions of viruses or bacteria, as
will be explained. The present high degree of contamination-free delivery provided
by the present invention was not heretofore possible.
[0042] Moreover, no validating evidence has been provided that conventional multidose delivery
systems can maintain the sterility of their products throughout use. In contrast,
the capability of the present invention to maintain the sterility of flowable media
challenged by bacteria or viruses is fully validated by experimental data contained
herein. Said data were obtained by an independent FDA-approved laboratory.
BRIEF DESCRIPTION OF THE DRAWINGS
[0043] These and other features, aspects, and advantages of the present invention will become
better understood with regard to the following descriptions, appended claims, and
accompanying drawings in which:
FIGURES 1A-1D are cross-sectional diagrams of typical fluid flow paths through the seats in conventional
systems for contamination-free delivery of a flowable material;
FIGURE 2 is a perspective view of a seat for a contamination-free delivery system in accordance
with an aspect of the present invention;
FIGURE 3 is an exploded view and cross-section of a device for contamination-free delivery
in accordance with an aspect of the present invention;
FIGURE 4 shows a cross section of a delivery system in a closed position in accordance with
an aspect of the present invention;
FIGURE 5 shows a cross-sectional diagram of a fluid delivery system;
FIGURE 6 shows a cross-sectional diagram of a seal comprising a shape memory material in a
closed position in accordance with an aspect of the invention;
FIGURE 7 shows an exploded perspective diagram of a delivery system incorporated in a tube
for delivering a fluid, including a flowable viscous material in accordance with an
aspect of the invention;
FIGURE 8 is a perspective view of a seal, seat and actuator in accordance with an aspect of
the present invention;
FIGURE 9 is a cross-sectional view of the embodiment of FIGURE 8;
FIGURE 10 is an exploded perspective view of an embodiment of an actuator, seat and seal for
carbonated beverages in accordance with an aspect of the present invention;
FIGURE 11 is a diagram showing a delivery system incorporated in a soda fountain or the-like
for dispensing a flowable material in accordance with an aspect of the present invention.
DETAILED DESCRIPTION
Conventional Contamination-Free Dispensing Systems
[0044] The seats or delivery blocks of conventional systems for dispensing flowable material
are shown in
FIGS. 1A-1D. For ease of description, their elastomeric seals have been omitted. In particular,
these figures show the complex flow path which a fluid takes through the seat in order
to exit the dispensing system for use. Referring to
FIGS. 1A-1D, depending upon the type of valve or delivery system used, a valve
10 includes an entrance port
12 for receiving a flowable material. The arrows indicate the flow path of the flowable
material into the entrance port
12 and through the valve
10. Each delivery system also includes an exit port
14. As is well understood by those skilled in the art, a seat is provided with an aperture
for receiving the flow path of flowable material and for transferring the material
to the exit port
14 in the direction of the arrows shown in
FIGS. 1A-1D, respectively. An elastomeric or other deformable seal (not shown) provides a means
for closing or opening the flow path for the flowable material to go through the seat,
pass between the seat and seal, and exit the outlet port. Note that in
FIGS. 1A-1D details of valve operation are omitted in order to show the complex flow path. The
flow path of a conventional delivery device typically makes three or four changes
in direction, each change slowing the delivery of the flowable material. Increases
in the applied pressure are required. To maintain satisfactory flow rates, several
pounds of pressure are required. In addition, the delivery devices, as shown in
FIGS. 1A-1D, are not suited to the delivery of viscous materials. Aside from requiring still
greater pressures for its delivery, a viscous material may become entrapped in corners
or constricted portions of the convoluted flow path and prevent the seal from fully
closing.
[0045] Other disadvantages arise from the convoluted flow paths of conventional dispensing
devices as shown in
FIGS. 1A-1D. One disadvantage is the unevenness of flow and lack of control over the flow rate
due to the complex flow path. This is particularly troublesome when attempting to
deliver highly viscous materials.
[0046] Another disadvantage relates to the inability to precisely cut off the flow of a
flowable material once the elastomeric member is placed in the closed position. Some
of the fluid is retained in the relatively long, tortuous flow path, even after the
elastomeric member has been closed. The retained fluid would be subject to contamination,
and would in turn contaminate successive doses of fluid. In addition, fluid left in
the convoluted flow path would tend to prevent the elastomeric member from seating
and closing properly, resulting in leakage as well as providing avenues for the entrance
of bacteria, viruses, or other contaminants. This would be detrimental to labile medications,
and would allow the entrance of air, causing contamination, oxidation and decreased
efficacy of the medication.
Dispensing Assembly For Producing Direct, Laminar Flow With Contamination-Free Operation
[0047] In accordance with an aspect of the present invention,
FIG. 2 shows an improved dispensing assembly seat
100 which is capable of producing direct laminar or linear flow of a flowable material
in the direction of the arrows shown. This is a simplified dispensing device which
also provides substantially complete and instantaneous truncation of the flow of flowable
material once the closure of the device is activated.
[0048] In
FIG. 2, a dispensing assembly
200 comprises a seat
100, a seal
110 and a housing
120. The seat
100 comprises a plurality of vanes
104. The vanes are axially arranged around a central blocking portion
106. A peripheral surface
102 of seat
100 defines a direct, linear flow path for the flowable material. That is, the peripheral
surface-of the seat-constrains the flowable material to assume a tube of flow.
[0049] It will be appreciated that the vanes
104 each have a major surface for defining the flow path. Each vane
104 extends radially outward from a center blocking portion of the seat. When the seat
100 is in the open position, the flowable material is directed by the vanes
104 in substantially direct fashion through the seal
110 and out of the exit port
122 in the housing
120 (see
FIG. 3). The vanes
104 help to ensure that the flowable material retains a substantially linear tube of
flow through the entire dispensing assembly.
[0050] The vanes
104 could also be viewed as sectors which impart unidirectional laminar flow to the flowable
material. An equivalent structure for the seat would comprise a series of parallel
channels for constraining a tube of flow through the seat. In this case, the blocking
portion would comprise the space between the channels.
[0051] It is understood that the seat can comprise but a single vane. Alternatively, the
seat
100 may be described as a tube having a peripheral surface
102. The blocking portion
106 need not be centrally located as shown. What is important is that the peripheral
surface
102 of the seat
100 must constrain the flowable material to assure a tube of flow through the seat. A
tube of flow may be defined as a flow path comprising a series of flow vectors or
streamlines. Turbulent flow is eliminated.
[0052] As will be explained in greater detail
infra, the peripheral surface
102 of the seat
100 and bore
112 of the adjacent seal
110 constrain the flow path so that flow can be effected substantially without separation
of a boundary layer sufficiently downstream of the seal
110 and exit port
122 such that no reverse flow or reflux occurs and no air or external contaminants can
return through the exit port
122. The tube of flow reduces the volume of a boundary layer in the seat and bore of the
seal to a point which is insufficient for the motility of microorganisms.
[0053] It is understood that in
FIGS. 2 and
3, the entrance to the seat is connected to a container of flowable material. The seat
also may be integrally formed in the neck or outlet end of a container of flowable
material.
[0054] In operation, the vanes
104 of the seat each has a major surface which is parallel to the flow path of the flowable
material. The vanes extend outward radially to the peripheral surface of the seat
and impart strength to the seat. The vanes minimize resistance to flow and direct
the flow path of the flowable material in a substantially constant uniform direction
through the seal and through the outlet port
122. In contrast to conventional devices, the flow path of the flowable material remains
direct and linear between an inlet or entrance pon
107 of the seat
100 and the outlet port
122 of the housing
120. The vanes ensure the linear flow of the fluid, such that internal resistance to flow
is minimized. Also, the volume of a boundary layer is reduced or substantially eliminated
so as to be insufficient for the motility of microorganisms.
[0055] In accordance with the invention, the geometry of the vanes
104 also can be designed to provide an optimized cracking pressure for the release of
fluid. That is, the top surface or seal contacting edges 108 of the vanes also define
the shape of the surface of the seat which contacts the elastomeric seal. The locus
of all seal contacting surfaces of the seat impart a predetermined shape to the seal
when the seal and seat are locked together in a seal tight engagement. This shape
can be varied in order to impart a predetermined stress or pressure on the elastomeric
seal. The shape of the vanes and surface of the seat in contact with the seal can
be changed to provide an optimized cracking pressure for the release of flowable material.
Cracking pressure is the activation threshold pressure at which point the fluid flows
through the entrance port and central bore of the seal. It will be appreciated that
the ability to control the pressure placed upon the seal by the geometry of the seat
conformably contacting the seal is a -major factor in ensuring that the flow of the
material through the dispensing assembly can be precisely controlled to a greater
degree than was heretofore possible. The flow remains, at all times, direct and laminar
and once the seal is closed, flow is instantaneously and completely cut off and there
are no spaces where excess flowable material could be concentrated to contaminate
successive releases of fluid or provide avenues for air or for microorganisms to enter
the dispensing assembly.
[0056] A seal
110 is provided for conformably contacting the seat
100 at a sealing surface
114. The seal has a bore
112 for admitting flowable material from the seat. The bore
112 is coextensive with or smaller than the blocking portion 106 of seat
100. The bore
112 is coaxially aligned with the blocking portion of the seat for enabling unidirectional
flow through the bore and out to exit orifice or outlet 116 which is disposed in exit
port
122 of housing
120 when the seal
110 and seat 100 are in an open state.
[0057] Referring to
FIG. 3, the seal comprises a reversibly deformable elastomeric material which contains a
bore to admit a tube of flow from the seat. The seal is designed such that the bore
conformably contacts the blocking portion of the seat in a first or closed position
(shown in
FIG. 4). In the closed position, the arcuate shape of the top of the seat (produced by the
locus or seal contacting surfaces of the seat) imparts a pressure to the elastomeric
material of the sheath and ensures a seal-tight, closed position in which pressure
from the elastomeric sheath is constantly exerted against the seat. In a closed position,
the pressure exerted by the elastomeric sheath prevents the flow of any material from
the seat.
[0058] The seal and seat cooperate to provide two states for the dispensing assembly. In
a first or closed state (shown in
FIG. 4), the exit port in the seal is blocked by a solid portion of the seat, wherein the
seal is held strongly against the seat, either by pressure produced by the elastomeric
material against the arcuate shape of the seat, or by an internal pressure from the
flowable material (when the seat is disposed downstream in the flow path from the
seal). In a second state (shown in
FIG. 5), the seal is separated from the seat, either by a negative pressure such as by pulling
or pushing the seal or by increasing the internal pressure of the fluid or by applying
pressure to the fluid reservoir.
[0059] It will be appreciated that the sealing surface 114 between the seal and seat is
greatly facilitated by having smooth mating surfaces for the seal, the solid part
of the seat and in some cases, the housing. Please refer to U.S. Patent Application
Serial No. 09/193,264, incorporated by reference herein. This requires the following
special care in the design of the molds and choice of the processing parameters for
manufacture of the component parts:
(1) An asymmetric mold is used so the mold parting lines occur outside critical surfaces
of the molded parts. (2) In addition, gates that could leave "flash", are placed in
regions where critical defect-free surfaces are unnecessary. (3) On preparing molds,
certain critical surfaces are highly polished approximating the finish of a diamond.
(4) Process parameters are selected and monitored to minimize the occurrence of knit
lines due to the confluence of plastic flow fronts as they fill the mold and may solidify
too quickly. Consequently, parts made from these molds have functional sealing surfaces
that are very smooth and conformably mate and separate during the reversible transition
between closed and open states. This substantially eliminates any unconformities or
air gaps which either could trap microorganisms, retain fluid that could impair sealing
of the device or provide an avenue for leakage or backflow contamination.
[0060] A further aspect of the invention is that the durometer of the elastomeric seal is
variable and can be selected to directly increase the pressure exerted by the combination
of the seal and seat against the flowable material. The durometer in accordance with
this aspect of the present invention can be much higher than is disclosed in conventional
systems.
[0061] This is made possible by the geometry of the seal and the strong engagement between
the housing
120 and seat
100 which anchors the seal
110 in place. The seal further comprises a reinforced annular portion
116 disposed about the exit of the bore
112. The reinforced annular portion
116 fits over the exit port
122 of the housing
120 as shown in
FIGS. 4 and
5.
[0062] The periphery of the seal
110 is also reinforced and widened along the longitudinal axis to provide a rim to conformably
engage and fit into a complimentary annular recess
124 in housing
120. The periphery or rim of the seal also conformably fits over the peripheral surface
102 of the seat to completely constrain the flow path of flowable material from the seat
and to direct the flowable material through the bore
112 and out the outlet
116.
[0063] The outer periphery of the seat
100 also includes a reinforced portion
130 for mating against the reinforced periphery or rim of the seal
110.
[0064] This geometry provides a strong engagement for anchoring of the seal and enables
a repeatable transient-free response of the seal to transition between an open and
closed position with respect to the seat. This also enables the durometer of the seal
to be greatly increased in comparison with conventional devices and to eliminate jitter
and uneven closure.
[0065] For example, U.S. Patent No. 5,305,786 sets a maximum upper limit of durometer as
70A. Also, a preferred range of durometer in this conventional dispensing system is
in a range of 25-55A (column 3, lines 24-27). The limited range of durometers disclosed
in conventional dispensing devices precludes their use in high pressure applications
such as for carbonated beverages, safety devices and the like. Further, the limited
durometer of conventional devices is a factor in limiting the response and effectiveness
of their seals. This contributes to the entrapment of fluid between the elastomeric
seal and delivery block, thereby serving as a contamination source.
[0066] Referring to
FIGS. 4 and
5, the dispensing apparatus according to an aspect of the present invention, is shown
in a closed state and an open state, respectively. This particular embodiment is suitable
for attachment to or integration into the neck of a volumetrically reducible container
holding a quantity of flowable material.
[0067] In
FIG. 4, the seal
110 is held tightly and conformably against the solid portion of the seat
100. The sealing surfaces
114 between the seal and seat contain imperfections less than 5 µm (microns) in height
and depth. The molds used to fabricate the seal
110 and seat
100 are highly polished, particularly where the molds form functional or sealing surfaces
of the seal
110 and seat
100 and, when used, the housing
120. This has the advantage of eliminating any unconformities, defects, or air pockets
which either could trap or provide an entry for microorganisms or leakage of the device.
[0068] All parting lines and knit lines are carefully kept out of the flow path. Thus, as
shown in
FIG. 4, the seal
110 and seat
100 are pressed conformably against one another in a seal-tight arrangement at sealing
surface
114 thereby substantially eliminating the occurrence of unconformities or air pockets.
[0069] The upper edge of the vanes
104 which contact the seal
110 at sealing surface
114 can be shaped to exert a specified pressure against the elastomeric seal in order
to provide an optimized cracking pressure for discharging a viscous material. The
optimized cracking pressure can be selected to provide ease of flow. In the case where
the viscous material is difficult to flow, the locus of all the seal-contacting edges
of the vanes at sealing surface
114 and blocking portion
106 of the seat may be configured to exert a specific pressure against the elastomeric
seal, thereby ensuring that a minimum application of external pressure would be sufficient
to activate the cracking pressure of the viscous material, and remove the seal from
the seat. At the same time, the vanes
104 provide a unidirectional laminar flow of the material through the seat and bore
112 fo the seal.
[0070] The geometry of the vanes
104 and blocking portion
106, which form an arcuate sealing surface
114, could be varied so as to impart a predetermined pressure against the seal
110. In so doing, the flow of a viscous material can be reduced, i.e., made more difficult
to provide safety factors, as required for childproof tubes and so forth.
[0071] Referring to
FIG. 4, a seat
100 comprises a solid or blocking portion
106 and a peripheral surface
200 for constraining a flow path to assume a tube of flow. Peripheral surface
200 can be coextensive with bore
107. A reversibly deformable seal
110 is provided with a thickly reinforced, extended rim
210. The rim
210 is strongly anchored between housing
120 and a reinforced outer portion
130 of the seat
100. The reversibly deformable seal is characterized by a memory effect and is responsive
to an applied positive or negative pressure for transitioning between a closed position
with respect to the seat
(FIG. 4) and an open position with respect to the seat
(FIG. 5). The seal comprises a bore
112 including an outlet orifice
116. The bore is coaxially aligned with the blocking portion of the seat for enabling
the tube of flow path from seat in the open position and for blocking the tube of
flow in the closed position. The seal bore and sealing surface
114 are disposed for airtight engagement against the seat along sealing surface
114 which completely blocks flow in the closed position.
[0072] In an aspect of the invention, the transition from the open to closed position is
characterized by a contraction of the seal
110 from the periphery in rim
210 toward the center of bore
112 along the sealing surface
114. This strong contraction in the transition to the closed state is believed to generate
an impulse wave which expels residual flowable material sufficiently downstream from
the exit orifice
116 so as to completely eliminate reflux or backflow. The impulse wave also expels any
film or boundary layer on the inner surface of bore
112.
[0073] All flowable materials have cohesion and adhesion properties and forms of molecular
attraction. Generally, the more viscous the fluid, the more pronounced are these affects.
These properties create capabilities known as surface tension and capillarity. A flowable
material will wet at a surface with which it contacts and under static conditions
leave a small film of said material. Although surface tension effects are generally
negligible in most engineering situations, they are important in the formation of
drops and bubbles, the breakup of liquid films and in small mechanisms. These effects
are the primary transport mechanism for contamination as these films or residues left
in conventional small valve nozzle areas can provide a transport mechanism for microbes
to contact film and migrate upstream of the seal. Accordingly, an aspect of this invention
provides a mechanism that expels all the film trapped in the valve during transition
from an open to closed state. Any remaining fluid material is arrested at the sealing
surface
114 between the seal and seat and provides a barrier to any transport mechanism for contamination
of the reservoir material. Any remaining matter is then flushed out upon the next
use. Thus, residual flowable material which is arrested or entrapped at the sealing
surface
114 between the seal and seat apparently is limited to one or more molecular layers which
form a barrier to the entry of air and are insufficient to support the motility of
microorganisms upstream of the sealing surface. Thus, repeatable non-contaminated
doses can be administered without adding contaminated residue.
[0074] In an embodiment shown in
FIG. 6, the reversibly deformable seal
110 comprises a shape memory material such as a Titanium Nickel alloy (TiNi) or the like,
characterized by a memory effect. The transition of a shape memory material from a
first state to a second state at an activation threshold temperature is well known.
As is well understood by those skilled in the art, a means for effecting the phase
transformation of the shape memory material commonly comprises applying an electric
current to a resistive heating means for heating the shape memory material to a phase
activation threshold. However, the means for effecting a phase transformation need
not be limited to an electric current, but rather can be any energy field sufficient
to induce a phase transition of the shape memory material. Resistive heating means
214 are provided on the downstream side of sealing surface
114. A microprocessor/ controller
218 is connected for providing a threshold activation current to resistive heating means
214 over lead
220 in accordance with techniques which are well known. Resistive heating means also
could be provided in the seat, at any convenient surface portion of the seat which
contacts the seal at sealing surface
114. In this case, the microprocessor controller would provide a threshold activation
current to the seat in accordance with techniques which are well known. The seal contacting
portion of the seat is used to resistively heat the seal to its activation threshold
and move the seal to an open position. The temperature of the flowable material moving
through seat
100 or bore
112 of the seal
110 would determine the speed of the transformation back to the closed state. This process
could be used for providing a precisely controlled metered delivery of flowable material.
[0075] The reversible transformation of the seal comprising a shape memory material would
still take place along the angled sealing surface
114 and thus provide a phased closure or concentric contraction toward the bore to provide
the self-cleansing sealing effect described above.
[0076] It will be appreciated that the durometer of the seal, in combination with the geometry
of the seal-contacting surfaces of the vanes and blocking portion of the seat, can
be configured so as to provide a strong restorative force to the seal sufficient to
clear the flow path of product, even viscous material. This provides a strong locking
seal-tight engagement that is stronger than is possible in conventional devices. This
restorative force automatically truncates the flow of a flowable material. The application
rate of a flowable medium, such as viscous medication or the like, is enhanced while
the entry of external contaminants is prevented. It will be appreciated that the geometry
and cooperation of the seal and seat, in combination with the engineering parameters
used to fabricate the seal and seat, serve to eliminate any unconformities in the
flow path. This aspect of the present invention is effective in preventing contamination,
even upon direct immersion of a system in viral or bacterial solutions, as will be
explained.
[0077] It will also be appreciated that an aspect of the present invention eliminates dead
volume in applying viscous substances from a conventional squeeze tube. For example,
more than 98% of the viscous material can be delivered from a tube -in a substantially
constant and uniform-manner, due to the complete elimination of reflux, backflow,
or entry of air. In addition, the contents of the tube can be used substantially indefinitely
without their degradation. Accordingly, the contents of the tube can be reformulated
without preservatives or other additives. This is especially valuable for pharmaceutical
products, such as salves and ointments.
[0078] In addition, the apparatus, according to this aspect of the invention, can be scaled
up or down in size to accommodate extremely large or extremely small volumes of flowable
material. In all cases, the geometry of the seat, including the vane or vanes ensures
that the flow path remains linear and that internal resistance to flow is minimized.
This also enables flow to be truncated cleanly, providing a sanitary feature. No excess
material remains to provide avenues for entry of any contaminants.
[0079] FIG 7 is an exploded view that shows an application of the dispensing device within a volumetrically
reducible container for dispensing a fluid material. This application would work for
materials having viscosities extended up to many thousands of centipoise, such as
honey, grease, caulking agents, paints, varnishes, or the like.
[0080] Application of pressure on the seal displaces the seal from engagement with the seat
and allows flow of material between the seat and the seal and out the exit port. Thus,
the seal and seat cooperate to provide two states. In a first state, the exit port
in the seal is completely blocked by a solid central blocking portion of the seat
(shown in
FIG. 4). In a second state, the application of pressure on the seal opens the seal and allows
fluid to flow (see
FIG. 5).
[0081] It will be appreciated that the seal also can be placed upstream in the flow path,
between the seat and the container of flowable materials shown in
FIG. 10. For example, with a carbonated beverage such as soda or beer, the internal pressure
of the flowable material would provide the restorative force for sealing the seal
strongly against the seat. In this arrangement, the carbonation of a flowable material
could be maintained for a period substantially equivalent to the shelf life of that
material.
[0082] Referring to
FIG. 7, the internal pressure on the fluid is increased by compression on the walls of a
flexible container by reducing the volume of the container or by other well known
means. This pressure forces the elastomeric seal
110 from its conformable position on the seat
100. As previously explained, the durometer of the seal
110 is adjusted to optimize the cracking pressure or activation threshold at which fluid
flow occurs. Alternatively, the optimized cracking pressure can be increased for safety
considerations.
[0083] Note that for this embodiment, the seat
100 is in direct contact with the fluid and is disposed upstream in the flow path relative
to the seal
110. In this case, a housing for holding the seat
100 and seal
110 in conformable locking engagement is provided by the interior surface of the neck
124 of the volumetrically reducible container or tube
130. Either the seal or seat may be integrally fabricated with the neck of the container.
It will be appreciated that this provides a volumetrically reducible container of
substantially two components which is simple and cost effective to manufacture, while
at the same time, providing a substantially complete protection against airborne contamination
or contamination by direct contact with viruses or bacteria. This provides a heretofore
unattainable seal which enables the integrity of the flowable material to be maintained
throughout its use, in many cases attaining the shelf life of the flowable material.
This also enables a labile medication to be formulated without antimicrobial agents
or other additives, and thus greatly enhance the medication's therapeutic effect eliminating
side effects of these additives. The use life of preservative-free thermostable flowable
materials can be extended to their shelf life without requiring refrigeration. It
should be worth noting that nearly 70% of the world's population presently has no
access to refrigeration.
[0084] FIG. 8 shows an exploded view of an embodiment including a housing
120 and integral lever
134 for effecting the transition between closed and open states of the seal
110 and seat
100. In this particular embodiment, a housing
120 is provided for holding the seal
110 and seat
100 in operational engagement. It will be appreciated that the seal
110 also may be tethered in operational engagement with the seat
100 or maintained in operational engagement by other well known means for allowing a
transition between a closed and open state of the seal
110 and seat
100. The seal
110 is shown downstream from the housing
120 with respect to the flow path of the material. The central bore
112 of seal
110 is disposed for locking engagement with the central blocking portion
106 of seat
100, when in an enclosed position. The seat
110 is provided with a reinforced portion
210 located at its periphery for assisting the seal
110 in returning to the closed state. Another reversibly deformable reinforced portion
116 is disposed around the outlet bore
112 of the seal
110 for engagement with the housing
120 and actuator
134. Actuator
134 contains lever
140 and includes delivery spout
144 or other means for directing the flow once it exits the bore
112. Lever
140 pulls the seal
110 off the blocking portion
106 of the seat
100, thereby enabling fluid to flow directly through the vanes 104 in the seat 100 and
out the central bore
112 of the seal
110. A housing
120 is provided for protecting the seal
110. It will be appreciated that in an open position the flow path of the fluid material
is directed by the radially-disposed vanes
104 of the seat
100 into a linear, direct flow that is coaxial and unidirectional with the bore
112 of seal
110.
[0085] In
FIGS. 8 and
9, an actuator
134 integral with a housing
120 provides a means for moving the seal
110 and seat
100 between a first closed state and a second open state. The housing
120 also provides an enclosure for maintaining the seal
110 and seat
100 in operational engagement.
[0086] This embodiment minimizes the surface area of the seal
110 and seat
100 in contact with the flow path, while providing a unidirectional, linear, high volume
flow in an open state. Actuator
134 is attached to lever
140 and housing
120 such that the mounting tabs
124 shown on the housing
120 penetrate channels
136 on actuator
134 and snap in place to attach the housing
120 to the actuator
134. The lever
140 includes projections
150 on its under surface for pulling the seal
110 away from the seat
100 to effect fluid flow.
(FIG. 9).
[0087] The lever
140 also can include tamper evident tabs
146 molded to the lever
140. Upon the first use, the tabs
146 break away from lever
140. When the tabs are affixed, this clearly indicates to a user that the dispensing system
has not been tampered with or used.
[0088] Fig. 10 shows an alternate embodiment for maintaining the carbonation of a flowable medium
without degradation over time. The seat
100 is located downstream of the seal
110, and would lie adjacent to an actuator
134. A typical actuator contains a pushbutton
142 disposed for reversibly moving the seal-seat engagement from a closed to open position.
A typical actuator is fitted with projections
(144) on an end thereof. On depression of the pushbutton
142, the projections
144 move through the apertures located in vanes or periphery of the seat
100 and deflect the seal
110 for transition between closed and open states.
[0089] In
FIG. 11, a delivery system in accordance with an aspect of the present invention is provided
for dispensing a flowable material, such as a soft drink or other beverage, from a
fountain or vending machine. As is well known, the beverage fountain contains a diffuser
unit
310 through which beverage components such as water, flavored syrup and carbon dioxide
gas, or similar ingredients flow to be mixed and dispensed to the inlet
107 side of a seat
100 as previously described. The seat
100 and the seal
110 reversibly transition between an open and closed state at sealing surface
114. As previously described, the transition to the closed state creates a self-cleaning
impulse wave which expels flowable material, including any film or boundary layer
out of the bore
112. At the same time, the flow of the material through the seat
100 is truncated at sealing surface
114. Any residual flowable material is entrapped at the sealing surface
114 and forms a monolayer barrier to the entry of air or any external contaminants. It
will be appreciated that this aspect of the invention prevents any contamination whatsoever
of the flowable material upstream of the dispensing system.
[0090] The contamination-safe dispensing system, in accordance with the above aspects of
the present invention, can be located downstream from and immediately adjacent to
a diffuser system. A diffuser system, wherein a syrup or other additive is mixed with
a beverage, can be integrated into the present dispensing system. The integrated dispensing
system would enable the flowable media to be mixed in a protected environment. The
beverage components would be kept completely safe from any airborne or other type
of contamination or breakdown. This advantageously would enable reformulation without
preservatives, additives, or other agents while extending the product's useful life..
Thus, such a device would ensure improved purity of a flowable material over what
is presently possible.
[0091] The molding process parameters will vary depending on the materials, size of the
parts, and specific features of the molding machine. However, in all cases these processing
parameters should be chosen to minimize flaws, such as of flow and knit lines. In
addition, the mold should be designed so that parting lines and flash at the gate
do not occur on functional sealing surfaces of the molded parts. The specific process
and mold design parameters are well known to one skilled in the art, and can be readily
duplicated without undue experimentation.
[0092] The seal, seat, housing and actuator component parts are made preferably of moldable
materials. The seal can be made from various thermoplastic elastomeric materials,
such as silicones, styrene-butadiene-styrene block copolymers, polyurethanes, rubber,
and the like. It also can be made from a shape memory material such as TiNi. The seat,
housing, and actuator can be made of thermoplastic or thermosetting resins. Exemplary
materials include high and low density polyethylene, polyvinyl chloride, Barex®, polypropylene,
polystyrene, polycarbonate, polyesters, poly(methylmethacrylate), carbon composites,
and the like.
[0093] The dispensing and delivery system provided by the present invention advantageously
protect flowable materials from the adverse effects of evaporation, oxidation, and
hydrolysis. The present dispensing and delivery system advantageously prohibits the
entry of the following contaminants into a flowable medium contained within the dispensing
and delivery system:
(1) microorganisms, such as protozoa, yeast, molds, bacteria, and viruses; (2) air
and any of its constituent parts, such as nitrogen, oxygen, carbon dioxide, and water;
(3) dust, smoke, pollen, and filamentous or other particulates; (4) airborne or bloodborne
pathogens, such as, for example, the HIV or Hepatitis-B virus; or (5) the evaporation
or breakdown of the flowable medium by one or more of its constituents.
[0094] The dispensing and delivery system, according to the present invention, advantageously
eliminates the need for filters, antimicrobial preservatives, antioxidants, hygroscopic
agents and, in some cases, the need for refrigeration. This has the advantage of providing
for substantial benefits in increased purity of the flowable material, the ability
to maintain sterility of the material over its entire useful life, ease of formulation
of the flowable material without the need for preservatives, antimicrobial agents,
and so forth, reduction in shipping and storage costs and a reduction in damaging
or harmful side reactions.
[0095] It will be appreciated that the present dispensing and delivery system also has the
advantage of maintaining the sterility and integrity of a flowable medium contained
within the system. This effectively prolongs the useful life of the flowable medium
to that of the shelf life. This also permits the distribution of a flowable medium
in larger sized containers without the need for refrigeration, thereby permitting
a reduction in cost per unit volume of the fluid and an economy of scale and decreased
shipping and storage costs.
[0096] The foregoing advantages of the present delivery and dispensing system were proved
in laboratory testing. The effectiveness of the present dispensing and delivery system
against viral and bacterial challenges are set forth in the following two examples.
Example 1
Viral Challenge Testing with ΦX714 Bacteriophage [Laboratory No. 131127]
[0097] This example describes test details for the viral challenge of Waterfall's MicroBarrier™
technology when used in a multidose system for the dispensing and delivery of aqueous
or viscous flowable materials. The system is designed to allow delivery of multiple
doses of viscous fluids over prolonged periods of time, while preventing the influx
of external contaminants.
[0098] Microbiological evaluation was conducted by attaching each of the following to one
of the three ports of a three-way stopcock with luer lock fittings: a 60 mL syringe
(the media reservoir), a MicroBarrier™ Cartridge (Model #WFLE2aVIS 97-60A), and a
3 mL syringe (for sampling the reservoir). The reservoir syringe was filled with sterile
soybean casein digest broth containing corn starch (SCDBC). Corn starch was added
to increase the viscosity of the growth media. To simulate use, an aliquot of sterile
SCDBC was dispensed each day through the test cartridge. Additionally, the tip of
the cartridge was contaminated by dipping it into a concentrated suspension of virus.
The test unit was allowed to incubate at room temperature between daily contaminations.
The challenge virus used in this study was bacteriophage ΦX174, prepared at a concentration
of approximately 10
8 plaque forming units per mL (PFU/mL).
[0099] Each day, an aliquot of the fluid in the reservoir syringe was collected in the sampling
syringe and assayed for the presence of the test organism. The study was conducted
for 21 days. The results were scored as "positive" if the challenge organism was detected
in the assay fluid, and "negative" if not. The study evaluated 30 sample cartridges.
Three positive and ten negative controls were also included in the study. A growth
promotion control was done to ensure that the media were capable of sustaining the
challenge organism.
Cartridge Preparation
[0100] Prior to testing, the cartridges were sterilized using ethylene oxide gas. Ethylene
oxide sterilization was performed according to the following parameters:

Challenge Preparation
[0101] Approximately 100 mL of nutrient broth was inoculated with
E. coli and incubated at 37 ± 2

C with rapid shaking [200-250 RPM] for approximately 6-18 hours to prepare the Φ174
bacteriophage. A 1/100 dilution of the culture was prepared and incubated at 37 ±
2

C. The culture was allowed to grow to a cell density of

2-4 x 10
8 CFU/mL [about 3 hours]. This cell density has a corresponding optical density of
0.3-0.5 when viewed spectrophotometrically at 640 nm. The bacterial culture was inoculated
with 5-10 mL of the ΦX174 bacteriophage stock [ATCC #13706-B1]. The ratio of bacteriophage
to bacterial cells was between 0.1 to 2.0. The suspension was incubated with rapid
shaking for approximately 1 to 5 hours at 37 ± 2

C. Complete lysis of the host bacteria was noted when the broth cleared. The virus
suspension was centrifuged at 10,000 x G for at least 20 minutes. The supernatant
fluid was filtered through a sterile 0.22 µm filter to remove the host cell debris.
The bacteriophage challenge suspension was prepared by diluting the phage stock in
sterile nutrient broth. The titer of the culture was determined for each day of testing.
Medium Preparation
[0102] Corn starch was added to SCDB (SCDBC) to achieve a viscosity of 1,600 to 2,400 cP
at 21 ± 2

C. The mixture was heated with constant stirring to boiling. The medium was sterilized
according to normal laboratory procedures. The viscosity of the medium was measured
at room temperature (21 ± 2

C) to ensure that it was within the acceptable range.
Assay Procedure
[0103] A sterile 60 mL syringe was aseptically filled with SCDBC. Inside a high-efficiency
particulate air (HEPA) filtered hood, a technician aseptically dispensed 1 mL of the
assay fluid from the reservoir syringe into a sterile test tube. This initial sample
was the time = 0 sample for that cartridge/syringe test unit. Gloves were worn during
this step and changed after every sample. The sample collection step was performed
on all samples and controls before proceeding to the next step.
[0104] After dispensing 1 mL, the 60 mL reservoir syringe was aseptically attached to one
port of a sterile 3-way stopcock having luer-lock fittings. A 3 mL syringe for sample
collection was then attached to another port of the 3-way stopcock. Finally, a test
cartridge was attached to the third port of the 3-way stopcock. Approximately 1 mL
of the SCDBC was dispensed from the reservoir syringe through the test cartridge.
The fluid dispensed was not collected for assay but was used simply to simulate use
of the test cartridge. The tip of the cartridge was then contaminated by immersing
it approximately 0.5 cm into the culture suspension. The contaminated culture completely
covered the opening of the cartridge without wetting the luer lock area. The entire
unit (syringes, stopcock and cartridge) was placed on a flat surface and allowed to
sit at room temperature (21 ± 2

C) for 24 ± 4 hours.
[0105] Following the 24-hour incubation period, a sample was collected from the reservoir
syringe. The port to the cartridge was closed and approximately 1 mL of media was
drawn out of the reservoir syringe into the sampling syringe. The syringe containing
the 1 mL sample was removed and set aside. It was replaced - by a sterile 3 mL syringe
which was used for the next day's sample collection. The samples then underwent the
dispensing and contamination steps. The testing was conducted for 21 days unless the
plaque assay detected virus in the samples collected from the syringe for four days
in a row, at which point further testing of the positive sample was terminated.
Controls
[0106] Ten negative controls and three positive controls were included in the testing program.
The negative controls consisted of sterile test units (reservoir syringe, sampling
syringe, 3-way stopcock and cartridge) prepared in the same manner as the test units,
except that the exit port of these cartridge units was sealed with a clear sealant
to prevent entry of virus into the system. The positive controls consisted of sterile
test units prepared in the same way as the test units, except that the elastomeric
sheath was slit, facilitating entry of the challenging virus.
[0107] A growth promotion test was performed on the media in the syringes of the test units
that were negative at the end of the test period. The test involved inoculating 1
mL of media from the reservoir syringe with 0.1 mL of viral culture containing < 100
PFU. A plaque assay was performed on the aliquot to determine if the challenge organism
was present.
Plaque Assay Procedure (Units Tested Against ΦX174)
[0108] The aliquot collected in the 3 mL sampling syringe was assayed for the presence of
ΦX174 by placing the 1 mL aliquot into 3 mL of molten (45 ± 2°C) top agar. Approximately
2 drops of
E. coli were added to the molten top agar, and poured over the surface of a bottom agar plate
and allowed to solidify. The plates were incubated at 37 ± 2°C for 18-24 hours. Results
were scored as "positive" or "negative", depending on whether the challenge organism
was detected in the assay fluid. "Positive" indicated the detectable presence of ΦX174
and "negative" indicated that ΦX174 was not detected.
Results
[0109] Assay results from the first week (
Tables 1A and
1B) demonstrated negative results for the negative controls and positive results for
the positive controls by day one. Testing of the positive controls was discontinued
after four consecutive days of growth. One sample cartridge (Number 15) had growth
on day 2. However, samples taken from this cartridge on subsequent days showed no
growth.
[0110] No growth was observed in any of the thirty test units during the second week (
Tables 2A and
2B) of testing. The negative controls remained negative.
[0111] Data from week three
(Tables 3A and
3B) demonstrated growth in four samples (cartridge numbers 4, 14, 20 and 25) and one
negative control (NEG 5) on three separate days (day 15, 17 and 21).
[0112] Since no test units demonstrated breakthroughs on consecutive days as would be expected
if the virus had actually passed through the cartridge, we believe that the plaques
assayed in the test samples are from environmental contamination. The occurrence of
growth in a negative control strengthens this position because the exit port of negative
controls were sealed with a clear silicone sealant that prevented entry of the challenge
organism through the cartridge.
[0113] Even the high titer of the spurious contamination seen in samples #4 and #15 can
be attributed to environmental contamination. The test virus is very stable and survives
drying well. Approximately 3.3 - 4.2 x 10
3 ΦX174 bacteriophage particles can be contained within a 0.1 µm particle. This is
well above the number of spurious plaques seen. The sedimentation rate of a 0.1 µm
airborne particle is approximately 0.115 inches per hour according to the U.S. Department
of Health. The test samples were maintained in an open laboratory and handled daily.
It should be noted that the challenge organism, ΦX174, will not grow in the test systems
and is non-motile. Consequently, it can gain entry to the test aliquots in only two
ways: through airborne contact during assay, i.e., via fluid aspiration whereby viral
organisms are dispensed in the air and contact the assay plate and/or transferred
across the cartridge by diffusion. Based on the characteristics of the challenge organism
and the results, the latter is unlikely. The plaques observed in this study are probably
due to cross-contamination with heavily contaminated syringes and devices.
[0114] A growth promotion test was done on a 1 mL aliquot of media taken from the reservoir
syringe of the 30 test samples and ten negative controls which did not have consistent
growth by day 21. The aliquots were inoculated with 0.5 mL of challenge culture containing
approximately 16 PFU. Growth was seen in all of the inoculated aliquots.
Discussion
[0115] Waterfall Company's MicroBarrier™ Cartridge for use in Multidose Dispensing and Delivery
Systems for viscous flowable materials is designed to prevent the influx of external
contaminants during and between deliveries over prolonged periods of time. The potential
for viral contamination is a concern for many flowable products, especially when dispensing
and delivering systems are used for discharging multi-use products and for products
which are used over prolonged periods of time.
[0116] The choice of a viral model to evaluate the barrier effectiveness of Waterfall's
technology is important for its use in excluding bloodborne pathogens. There are problems
associated with utilizing the actual bloodborne pathogens as test organisms. Hepatitis-B
virus (HBV) and Hepatitis-C virus (HCV) cannot be grown in the laboratory. Human immunodeficiency
virus (HIV) represents a significant safety and liability consideration due to its
high infectivity potential and requirements for extreme and expensive precautions.
[0117] Therefore, a model for the bloodborne pathogens was researched. The ideal properties-of
a surrogate would include small size, spherical or polyhedral [almost round] morphology,
environmental stability, low or non-human infectivity, high assay sensitivity, rapid
growth, and an attainable high titer. The ΦX174 bacteriophage was selected as the
most appropriate surrogate for the bloodborne pathogens mentioned because it satisfies
all of these criteria. The ΦX174 bacteriophage has no envelope and is 25-27 nm in
size [similar to HCV, the smallest pathogen], has an icosahedral or nearly spherical
morphology similar to all three viral pathogens mentioned, has excellent environmental
stability, is non-infectious to humans, has a limit of detection which approaches
a single virus particle, grows very rapidly [assay results can be read within as little
as 4-8 hours], and can be cultivated to reach very high titers similar to HBV [the
most concentrated pathogen mentioned].
[0118] Animal virus surrogates are not used as they require specialized cell culture and
enzyme assay techniques. In addition, the stability of most of the animal viruses
is less than desirable and plating efficiency is low or unknown. Despite the variety
of viral coats or surfaces [i.e., lipophilic, hydrophilic, etc.], they generally perform
similarly in barrier or penetration tests. This is because viruses adopt the charge
of the liquid in which they are suspended and are more affected by the liquid vehicle
than by their own physical or chemical properties.
[0119] In order to simulate the viscosity of the fluids for which this product is designed,
corn starch was added to the growth media at a concentration of 4 g/100 mL (4% w/v)
which results in an absolute viscosity of approximately 2,000 cP at 21 ± 2°C.
Summary
[0120] Over the three-week test period, 30 Waterfall MicroBarrier™ test cartridges were
challenged daily with ΦX174 (≈10
8 PFU/mL). The reservoir solutions in the syringe were tested for ΦX174 daily using
a plaque assay procedure using
E.
coli. Four of the 30 cartridges had plaques on one or more days. This corresponds to an
apparent barrier performance of 87%. However, because none of the test samples assayed
positive on successive days it is likely that these four positive test results are
due to environmental contaminants reprcsenting a baseline error. It is relatively
easy to aerosolize ΦX174 and have viral particles contaminate the sampling process.
[0121] Moreover, the presence of virus in the reservoir solution of the negative control
cartridge, having a silicone-plugged entry and exit port, indicates the viral particles
were airborne and did not break through the cartridge. Therefore, we believe that
the test sample positives on assays resulted from environmental contamination and
that Waterfall's MicroBarrier™ cartridges were 100% effective barriers in preventing
the entry of viral particles throughout the three-week test period.
[0122] By comparison, such barriers as surgical gloves and condoms may vary from lot to
lot and range from less than 50% up to 100% barrier performance, when tested with
the same virus over 60 minutes.
TABLE 1A.
Viral Challenge Results - Week 1 |
CARTRIDGE NUMBER |
TEST DAY NUMBER |
|
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
15 |
0 |
0 |
100 |
0 |
0 |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
20 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
21 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
23 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
24 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
26 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
27 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
29 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
30 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
[0123] Test results are given in plaque forming units (PFU).
TABLE 1B.
Viral Challenge Results - Week 1 |
CARTRIDGE NUMBER |
TEST DAY NUMBER |
|
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
POS #1 |
0 |
<10 |
<10 |
43 |
50 |
* |
* |
* |
POS #2 |
0 |
TNTC |
TNTC |
TNTC |
TNTC |
* |
* |
* |
POS #3 |
0 |
TNTC |
TNTC |
TNTC |
TNTC |
* |
* |
* |
NEG #1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
[0124] Test results are given in plaque forming units (PFU). *Testing of the positive controls
was terminated. TNTC = Too numerous to count.
TABLE 2A.
Viral Challenge Results - Week 2 |
CARTRIDGE NUMBER |
TEST DAY NUMBER |
|
8 |
9 |
10 |
11 |
12 |
13 |
14 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
20 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
21 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
23 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
24 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
26 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
27 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
29 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
30 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
[0125] Test results are given in plaque forming units (PFU).
TABLE 2B.
Viral Challenge Results - Week 2 |
CARTRIDGE |
TEST DAY NUMBER |
NUMBER |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
NEG #1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
[0126] Test results are given in plaque forming units (PFU).
TABLE 3A.
Viral Challenge Results - Week 3 |
CARTRIDGE NUMBER |
TEST DAY NUMBER |
|
15 |
16 |
17 |
18 |
19 |
20 |
21 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
TNTC |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
20 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
21 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
23 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
24 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
26 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
27 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
29 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
30 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
[0127] Test results are given in plaque forming units (PFU).
TNTC = Too numerous to count.
TABLE 3B.
Viral Challenge Results - Week 3 |
CARTRIDGE NUMBER |
TEST DAY NUMBER |
|
15 |
16 |
17 |
18 |
19 |
20 |
21 |
NEG #1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #5 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
NEG #6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
[0128] Test results are given in plaque forming units (PFU).
Example 2
Bacterial Challenge Testing With Brevurzdimonas Diminuta [Laboratory No. 129733]
[0129] The following example provides details for the bacterial challenge testing of Waterfall's
MicroBarrier™ Cartridge in Multidose Dispensing and Delivery Systems for viscous materials,
Model #WFLE2aVIS 97-60A. The system design is intended to allow delivery of multiple
doses of viscous fluids and prevent the influx of external contaminants over prolonged
periods of time.
[0130] Microbiological evaluation was conducted by attaching each of the following: a 60
mL syringe (the media reservoir), a MicroBarrier™ Cartridge, and a 3 mL syringe (for
sampling the reservoir) to one of the three ports of a three-way stopcock with luer
lock fittings. The reservoir syringe was filled with sterile soybean casein digest
broth containing corn starch (SCDBC). Corn starch was added to increase the viscosity
of the growth media. To simulate use, an aliquot of sterile SCDBC was dispensed each
day through the test cartridge. Additionally, the tip of the cartridge was contaminated
by dipping it into a concentrated suspension of bacteria. The bacteria used in this
study were
Brevundimonas diminuta at an average concentration greater than 1 x 10
8 colony forming units per mL (CFU/mL).
[0131] Each day, an aliquot of the fluid in the reservoir syringe was collected in the sampling
syringe and assayed for the presence of the test organism. The study was conducted
for 21 days. The results were scored as "positive" if the challenge organism was detected
in the assay fluid, and "negative" if not. The study evaluated 30 cartridges. Three
positive controls and three negative controls were also included in the study. A growth
promotion control was done to ensure the media were capable of sustaining the challenge
organism.
Cartridge Preparation
[0132] The test cartridges were sterilized by ethylene oxide gas prior to testing. Ethylene
Oxide Sterilization was performed according to the following parameters:

Challenge Preparation
[0133] Approximately 100 mL of soybean casein digest broth (SCDB) was inoculated with
B. diminuta and incubated at 30 ± 2

C for 24 ± 4 hours. A new bacterial culture was made and titrated for each day of
testing. Prior to using a new culture, the purity was verified with a spread plate.
This new culture was used to contaminate the tips of the cartridges.
Medium Preparation
[0134] Corn starch was added to SCDB (SCDBC) to achieve a viscosity of 1,600 to 2,400 cP
at 21 ± 2

C. The mixture was heated with constant stirring to boiling. The medium was sterilized
according to normal laboratory procedures. The viscosity of the medium was measured
at room temperature (21 ± 2

C) and found to be 2008 cP.
Assay Procedure
[0135] A sterile 60 mL syringe was aseptically filled with SCDBC. Inside a high-efficiency
particulate air (HEPA) filtered hood, a technician aseptically dispensed 1 drop of
the assay fluid from the reservoir syringe onto a soybean casein digest broth (SCDBA)
plate. This initial sample was the time = 0 sample for that cartridge/syringe test
unit. Gloves were worn during this step and changed after every sample. The sample
collection step was performed on all samples and controls before proceeding to the
next step.
[0136] After dispensing 1 drop, the 60 mL reservoir syringe was aseptically attached to
one port of a sterile 3-way stopcock having luer-lock fittings. A 3 mL syringe for
sample removal was then attached to another port of the 3-way stopcock. Finally, a
test cartridge was attached to the third port of the 3-way stopcock. Approximately
1 mL of the SCDBC was dispensed from the reservoir syringe through the test cartridge.
The fluid dispensed was not collected for assay but was used to simulate use of the
test cartridge. The tip of the cartridge was then contaminated by immersing it approximately
0.5 cm into the culture suspension. The contaminated culture completely covered the
opening of the cartridge without wetting the luer lock area. The entire unit (syringes,
stopcock and cartridge) was placed on a flat surface and allowed to sit at room temperature
(21 ± 2

C) for 24 ± 4 hours.
[0137] Following the 24-hour incubation period, a sample was collected from the reservoir
syringe. The port to the cartridge was closed and approximately 1 mL of media was
drawn out of the reservoir syringe into the sampling syringe. The syringe containing
the 1 mL sample was removed and set aside. It was replaced by a-sterile 3 mL syringe
which was used for the next day's sample collection. The samples then underwent the
dispensing and contamination steps. The testing was conducted for a minimum of 7 days
unless growth was detected in samples collected from the syringe for four days in
a row, at which point further testing of the positive sample was terminated.
Controls
[0138] Three negative and three positive controls were included in the testing program.
The negative controls consisted of sterile test units (reservoir syringe, sampling
syringe, 3-way stopcock and cartridge) prepared in the same manner as the sample test
units, except that the exit ports of these cartridge units were sealed with a clear
sealant to prevent entry of bacteria into the system. The positive controls consisted
of sterile test units prepared in the same way as the sample test units, except that
the elastomeric sheath was slit, facilitating entry of the challenging bacteria.
[0139] A growth promotion test was performed on the media in the syringes of the test units
that were negative at the end of the 21-day test. The test involved inoculating 1
mL of media from the reservoir syringe with 0.1 mL of a
B.
diminuta culture containing <100 CFU or <10 CFU when possible. The media was incubated for
24-48 hours at 37 ± 2°C. An aliquot of the media was then assayed to determine if
the challenge organism was present.
Assay Procedure For B. Diminuta:
[0140] The sample collected was assayed qualitatively for growth by placing a drop on SCDA
and incubating it for 24-72 hours at 37 ± 2°C. The remainder of the sample was saved
in a refrigerator in the event that a confirmation of results was necessary. Growth
occurring on the SCDA plate was tested biochemically to determine if the isolated
organism was
B. diminuta. A stain revealing Gram negative rods and a positive oxidase test was considered
confirmation of the challenge organism.
Results
[0141] No
B. diminuta growth was observed in any of the thirty test units during the first week of testing.
The negative controls were negative. The positive controls were positive for
B. diminuta by day one. Testing of the positive controls was discontinued after four consecutive
days of growth. The results from week one are detailed in
Table 4.
[0142] No
B. diminuta growth was observed in any of the thirty test units during the second week of testing.
The negative controls remained negative. The results from week two are detailed in
Table 5.
[0143] One sample (#26) was positive on days 16 through 19, so testing of this cartridge
was discontinued. The growth on the SCDA plate was tested and biochemically found
to be an organism other than
B. diminuta. Because this growth was not
B. diminuta, the cartridge was not considered to have failed the challenge. Testing was discontinued
because the contaminant might have prevented growth of the challenge organism had
it passed through the cartridge. No
B. diminuta growth was observed in any of the other 29 test units during the third week of testing.
The negative controls remained the same for the third week. The results from week
three are tailed in
Table 6. In summary, the 29 surviving samples successfully resisted breakthrough by
B. diminuta and represent a 100% effective barrier.
Discussion
[0144] The Waterfall Company's MicroBarrier™ Cartridge in Multidose Dispensing and Delivery
Systems for viscous materials, Model #WFLE2aVIS 97-60A was designed to prevent the
influx of external contaminants during and between deliveries.
[0145] The potential for bacterial contamination is a concern for many flowable products,
especially when dispensing and delivering systems are used for discharging multi-use
products and for products which are used over prolonged periods of time.
[0146] The selection of
Brevundimonas diminuta as the challenge organism was based on its small size when grown under carefully
controlled conditions. When properly cultured, many
Brevundimonas will pass through a 0.45 µm membrane filter. The small size of the organism represented
a severe bacterial challenge to the test cartridges.
B. diminuta is also the organism of choice for conducting membrane filter validation testing
for pharmaceutical processes. The rapid motility of this challenge organism, as well
as its possession of a sensory apparatus that drives the organism to nutrients, enhanced
the severity of the test challenge.
[0147] In order to simulate the viscosity of the fluids for which this product is designed,
corn starch was added to the growth media at a concentration of 4 g/100 mL (4% w/v)
which resulted in an absolute viscosity of approximately 2,000 cP at 21 ± 2°C.
[0148] The selection of daily dispensing of the nutritive media represented a severe challenge.
The daily contamination with a new culture and the 24 hours to permit growth through
the mechanism was more severe than a test which involves only frequent dispensing
steps. In addition, while the protocol required the challenge level to be >10
6, the average titer of the challenge used was actually >10
8.
Summary
[0149] The Waterfall Company's MicroBarrier™ Cartridges were challenged daily with
Brevundimonas diminuta, a small, highly motile bacterium. The challenge test procedure consisted of (1)
dispensing of nutritive media through the cartridge, (2) contamination of the cartridge
tips by immersing them into a concentrated bacterial suspension (10
8 CFU/mL), and (3) placing each cartridge and syringe on a horizontal surface for 24
hours incubation at 21 ± 2°C. The cartridges provided complete sterility for 21 days.
This corresponds to a 100% effective barrier against a daily challenge with 10
8 CFU/mL of
B. diminuta for three weeks.
[0150] The unique design of the device makes comparison to other conventional microbial
barriers difficult. However, the device performed comparable or superior to that seen
in our laboratory for 0.45 µm microporous membranes.
TABLE 4.
Bacterial Challenge Results - Week 1 |
CARTRIDGE NUMBER |
TEST DAY NUMBER |
|
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
+§ |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
20 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
21 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
23 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
24 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
26 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
27 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
29 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
30 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
POS #1 |
0 |
+ |
+ |
* |
* |
* |
* |
* |
POS #2 |
0 |
+ |
+ |
* |
* |
* |
* |
* |
POS #3 |
0 |
+ |
+ |
* |
* |
* |
* |
* |
NEG #1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Results were recorded as + (growth) or 0 (no growth)
* Testing of the positive controls was terminated. |
§ Sample was positive on one day. Due to the nature of the challenge organism, this
was likely due to laboratory contamination. |
TABLE 5.
Bacterial Challenge Results - Week 2 |
CARTRIDGE NUMBER |
TEST DAY NUMBER |
|
8 |
9 |
10 |
11 |
12 |
13 |
14 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
20 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
21 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
23 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
24 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
26 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
27 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
29 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
30 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
[0151] Results were recorded as + (growth) or 0 (no growth)
TABLE 6.
Bacterial Challenge Results - Week 3 |
CARTRIDGE NUMBER |
TEST DAY NUMBER |
|
15 |
16 |
17 |
18 |
19 |
20 |
21 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
20 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
21 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
23 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
24 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
26 |
0 |
+* |
+* |
+* |
+* |
+* |
+* |
27 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
29 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
30 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
NEG #3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Results were recorded as + (growth) or 0 (no growth)
‡Growth in syringe was determined to be a contaminant rather than B. diminuta. |
[0152] It will be appreciated that the foregoing aspects of the invention provide a system
for dispensing and delivering a wide range of flowable media, including liquids, solutions,
suspensions, dispersions, lotions, creams, gels, and salves. These flowable media
either can be volatile or non-volatile, aqueous or nonaqueous, and classified as inorganic
or organic fluids, as well as combinations thereof. The present invention has application
as a dispensing and delivery system for fluids used in any industry.
[0153] While the invention has been described in connection with what is presently considered
to be the most practical and preferred embodiments, it is to be understood that the
invention is not limited to the enclosed embodiments, but on the contrary, is intended
to cover various modifications and equivalent arrangements included within the spirit
and scope of the appended claims. For example, one or more vanes may extend across
the diameter of the seat. Likewise, the seat may comprise one or more sectors, or
one or more channels may be disposed through the seat such that each sector or channel
defines a unidirectional laminar tube of flow through the seat. A blocking portion
could be provided at any convenient location in the seat to occlude the bore of an
adjacent seal when the seal and seat are in a closed position. The blocking portion
need only be aligned in the flow path and shaped so as not to induce turbulent flow
when the seal and seat are in an open position.
[0154] The seat also can comprise a tube having an inlet and an outlet with a blocking portion
on an edge of the outlet. An adjacent seal has a bore having an inlet coextensive
with the blocking portion and an outlet orifice. The bore prevents flow when conformably
engaged against the seal in a closed state and enables flow in an open state, respectively.
In this embodiment, the bore does not need to be centrally located, but rather is
aligned with the blocking portion of the seat.
[0155] What is important is that the peripheral surface of the tube constrains the fluid
flow through the tube, and the bore of the seal similarly constrains the flow path.
Upon transition to the closed state, the seal still contacts at a sealing surface
with the seat to generate an impulse wave so that the flow is effected without separation
of a boundary layer sufficiently downstream of the seal outlet orifice such that no
reflux or reverse flow can occur. Any excess flowable material is entrapped at the
sealing surface and prevents air or any other external contaminant from migrating
back through the flow path. However, in such structures, the seat still provides unidirectional
laminar flow of a flowable medium along a flow path.
[0156] Therefore, persons of ordinary skill in this field are to understand that all such
equivalent structures are to be included within the scope of the following claims.